Obesity stories

Nov 8, 2026

Semaglutide improves cardiac structure and hemodynamics in heart failure with preserved ejection fraction

Two placebo-controlled trials presented at the 2026 AHA Scientific Sessions found semaglutide significantly improved cardiac structure, function, and pulmonary artery wedge pressure in patients with heart failure with preserved ejection fraction and obesity.

Nov 8, 20262 sources

Top claims

▪Researcher Barry A. Borlaug conceived and designed the CAMEO-SEMA study and prepared the first draft of the manuscript
▪Improvements in left atrial reservoir strain following semaglutide treatment were significantly associated with reductions in exercise pulmonary artery wedge pressure in the cardiac magnetic resonance substudy of the CAMEO-SEMA trial
▪The CAMEO-SEMA trial evaluated the hemodynamic effects of semaglutide in patients with obesity-related heart failure with preserved ejection fraction over a one-year period

Subtopics

Cardiovascular diseases1 Clinical trials1 GLP-1 receptor agonists1 Heart health1 Medical imaging1 Novo Nordisk1 Obesity treatment1 Randomized controlled trial1

Related timelines